Sarepta Plunges 50% After FDA Rejects Key Drug

2016 has been a tempestuous year for Serepta shareholders. From over $40 to just $10 and then the miracle ramp from february back to $25 before the writing on the wall ahead of last night’s FDA decision and now – following yesterday’s monstrous short-squeeze (36% surge), a 50% collapse to $8 – a 4 year low for yet another Biotech darling of old. This morning’s collapse comes after the FDA voted that SRPT’s muscular dystrophy drug was not effective



As Bloomberg reports,

An FDA advisory panel voted 7-3 with 3 abstentions that Sarepta’s single historically controlled study doesn’t provide substantial evidence that eteplirsen is effective for treatment of Duchenne muscular dystrophy (DMD).


Some panel members raised questions about study design, said more data are needed.

Not a great morning for Stevie Cohen who just upped his stake (seems he did not get the nod this time)…


Any questions, refer to Christopher Marai or Chad Messer (PhD!)…

The post Sarepta Plunges 50% After FDA Rejects Key Drug appeared first on